Dynavax Technologies Corporation Stock Nasdaq
Equities
US2681581029
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Financials (USD)
Sales 2024 * | 285M | Sales 2025 * | 350M | Capitalization | 1.48B |
---|---|---|---|---|---|
Net income 2024 * | 18M | Net income 2025 * | 48M | EV / Sales 2024 * | 3.23 x |
Net cash position 2024 * | 556M | Net cash position 2025 * | 683M | EV / Sales 2025 * | 2.27 x |
P/E ratio 2024 * |
70.5
x | P/E ratio 2025 * |
31.3
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.69% |
Latest transcript on Dynavax Technologies Corporation
Managers | Title | Age | Since |
---|---|---|---|
Ryan Spencer
CEO | Chief Executive Officer | 46 | 04-12-31 |
David Novack
PSD | President | 62 | 13-03-24 |
Patricia Novy
CTO | Chief Tech/Sci/R&D Officer | - | 20-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Francis Cano
BRD | Director/Board Member | 79 | 09-11-02 |
Peggy Phillips
BRD | Director/Board Member | 70 | 06-07-31 |
Dan Kisner
BRD | Director/Board Member | 77 | 10-07-21 |
1st Jan change | Capi. | |
---|---|---|
+8.65% | 114B | |
+11.33% | 104B | |
-12.73% | 22.41B | |
-1.05% | 22.28B | |
-5.29% | 19.07B | |
-38.29% | 18B | |
-4.07% | 17.89B | |
+7.97% | 14.28B | |
+35.31% | 12.55B |